Ebrantil - antiadrenergicheskim drug from the group of α 1 adrenoblokatorov.  Ebrantil capsules

By analogues Ebrantila by pharmacological group includes Omsulozin, Zokson, Alfazuzozin, Butiroksan, Dalfaz, hypersimple, yohimbine hydrochloride, Cardura, roots, Nicergoline, Omnic, pirroksan, Omsulozin, prazosin, Proroksan, Profloksin, Polpressin, Nilogrin, Camiri, Ditamin, Artezin, terazosin, Urokard, Fokusin, Setegis, Redergin, Urorek, Tamsulosin, Revokarin.

Structural analogues of the main active component drug Ebrantil not.

Structure and Composition

According Ebrantil instructions issued in the form of a solution for intravenous administration (in capsules of 5, 10 ml), and capsules (30, 60 and 90 mg).

Ebrantila 1 ml contains 5 mg of urapidil - the main active component of the drug. Auxiliary components: propylene glycol, sodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate dihydrate, water for injection.

A medicament capsule contains 30, 60 or 90 mg, respectively, urapidil. Additional components :   methacrylate copolymer (type B), talc, diethyl phthalate, hypromellose, fumaric acid, ethylcellulose, hypromellose phthalate, stearic acid, sugar spherical.

Pharmacological action Ebrantila

Ebrantil blocking postsynaptic α 1 adrenergic receptors, reduces peripheral resistance. In addition, little has Ebrantil expressed beta-adrenoceptor blocking action, is involved in the regulation mechanism for maintaining vascular tone. Cardiac output and heart rate when administered Ebrantila not change.

The drug reduces the balanced blood pressure (systolic and diastolic), reduces peripheral resistance, without causing reflex tachycardia.

Action urapidil contributes to reduced cardiac output, reducing the burden on the heart muscle and increase the efficiency of cardiac contractions.

In the CNS, the active ingredient of the drug affects the activity of vasomotor center, preventing reflex decrease (or increase) in the tone of the sympathetic nervous system.

Urapidil no way affects the exchange of uric acid and carbohydrate metabolism performance without causing fluid retention.

Ebrantil easily passes through the placenta and the blood-brain barrier. The maximum concentration of urapidil in plasma is reached after four to six hours after application Ebrantila. Most of urapidil is metabolized in the liver. Urapidil and its metabolites are excreted by the kidneys (55-70%), and through the intestines.


According to the instructions Ebrantil used for hypertensive crisis, refractory hypertension and for controlled lowering elevated blood pressure after and / or during surgery.

Ebrantil - Instructions for use

 The solution for infusion Ebrantil
 According to the instructions Ebrantil administered intravenously by continuous infusion or blasting. Capsules Ebrantil medication should be taken twice a day, morning and evening, during a meal, washed down with a small amount of liquid. When refractory hypertension, arterial hypertension severe, hypertensive crisis 10-50 mg administered intravenously Ebrantila under the control of blood pressure. Lowering blood pressure should occur within five minutes after injection. Depending on the therapeutic effect of possible re-introduction of the drug.

For continuous intravenous drip or injection using a perfusion pump. Maintenance dose - about 9 mg / hr, i.e. 250 mg of medicament are diluted in 0, 5 liters of a solution for injection. The maximum allowable concentration - 4 Ebrantila mg per 1 ml injection solution (5% or 10% glucose (dextrose) or saline). Speed ​​drip intravenous drug depends on the patient's blood pressure.

When using the blood pump 100 mg Ebrantila introduced into a syringe and diluted to 50 ml of 5% or 10% solution of glucose (dextrose) or saline.

At higher blood pressure after and / or during surgery with the aim of reducing the controlled drug Ebrantil administered intravenously at a dose of 25 mg. The decrease in blood pressure should occur within two minutes after the administration. Further stabilization of blood pressure performed by infusion.

If the stabilization of the parameters of pressure does not come for a long time, it is slow intravenous medication Ebrantil 50 mg.

If you have previously used other antihypertensive drugs, the Ebrantil can be administered no earlier than the start of the administration.

For the gradual reduction in blood pressure is applied to 30 mg of the drug twice a day.

The recommended dose Ebrantila to rapidly reduce blood pressure - 60 mg twice a day. Total urapidil should be from 60 to 180 mg per day.

Contraindications Ebrantila

  • aortic stenosis;
  • Children up to age 18;
  • pregnancy;
  • lactation;
  • hypersensitivity to Ebrantilu;
  • open arterial canal.

Caution should be used Ebrantil in old age, hypovolemia, and in violation of the kidney and / or liver.

side effect

With prolonged use Ebrantila may occur following adverse symptoms: vomiting, nausea, arrhythmias, shortness of breath, headache, nephropathy, dizziness. Sometimes there is itching, bradycardia or tachycardia, palpitations, anxiety, anemia, nephrotic syndrome.

Overdose Ebrantilom

Overdose symptoms Ebrantilom: orthostatic hypotension, dizziness, collapse, speed reduction reactions, fatigue.

Therapy: progressive reduction in blood pressure reduction by raising up the lower limbs, blood volume replacement; with no effect - the slow intravenous administration of vasoconstrictors. In rare cases, used intravenous catecholamines.

storage conditions

Storage Temperature - not exceeding 30 ° C.

Shelf life - 2 years.